Published in final edited form as:

Chem Biol Interact. 2011 May 30; 191(1-3): 250–254. doi:10.1016/j.cbi.2010.12.020.

The effect of disease associated point mutations on 5 β -reductase (AKR1D1) enzyme function

Rebekka Mindnich¹, Jason E. Drury¹, and Trevor M. Penning^{1,2,*}

¹ University of Pennsylvania, School of Medicine, Department of Pharmacology, Philadelphia PA 19104-6084

² Center of Excellence in Environmental Toxicology, Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104-6084, USA

Abstract

The stereospecific 5 β -reduction of Δ^4 -3-ketosterols is very difficult to achieve chemically and introduces a 90° bend between ring A and B of the planar steroid. In mammals, the reaction is catalyzed by steroid 5 β -reductase, a member of the aldo-keto reductase (AKR) family. The human enzyme, AKR1D1, plays an essential role in bile-acid biosynthesis since the 5 β -configuration is required for the emulsifying properties of bile. Deficient 5 β -reductase activity can lead to cholestasis and neo-natal liver failure and is often lethal if it remains untreated. In five patients with 5 β -reductase deficiency, sequencing revealed individual, non-synonymous point mutations in the AKR1D1 gene: L106F, P133R, G223E, P198L and R261C. However, mapping these mutations to the AKR1D1 crystal structure failed to reveal any obvious involvement in substrate or cofactor binding or catalytic mechanism, and it remained unclear whether these mutations could be causal for the observed disease. We analyzed the positions of the reported mutations and found that they reside in highly conserved portions of AKR1D1 and hypothesized that they would likely lead to changes in protein folding, and hence enzyme activity. Attempts to purify the mutant enzymes for further characterization by over-expression in *E.coli* yielded sufficient amounts of only one mutant (P133R). This enzyme exhibited reduced K_m and k_{cat} with the bile acid intermediate Δ^4 -cholesten-7 α -ol-3-one as substrate reminiscent of uncompetitive inhibition. In addition, P133R displayed no change in cofactor affinity but was more thermolabile as judged by CD-spectroscopy. When all AKR1D1 mutants were expressed in HEK 293 cells, protein expression levels and enzyme activity were dramatically reduced. Furthermore, cycloheximide treatment revealed decreased stability of several of the mutants compared to wild type. Our data show, that all five mutations identified in patients with functional bile acid deficiency strongly affected AKR1D1 enzyme functionality and therefore may be causal for this disease.

Keywords

5 β -reductase; AKR; bile acid deficiency

*corresponding author, penning@mail.med.upenn.edu.

Conflict of interest

The authors declare that there are no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. AKR1D1: a unique member of the AKR superfamily

Human steroid 5 β -reductase (AKR1D1) is a member of the aldo-keto reductase (AKR) superfamily, enzymes that exert important metabolic functions in organisms of all phyla [1]. The superfamily comprises over 150 annotated members that share 20–99% sequence identity. The AKR nomenclature [2] distinguishes 16 families (AKR1–16) based on a minimum of 40% protein sequence similarity. Family members with 60% or more sequence identity are further grouped into subfamilies (e.g. AKR1A–E). Hence, AKR1D1 belongs to the AKR1 family and the AKR1D subfamily.

Despite the observed low sequence conservation between distant members due to high evolutionary diversity, all AKR enzymes share three important characteristics: (1) a conserved protein fold that results in a characteristic (α/β)₈-barrel structure; (2) a conserved mode of cofactor and substrate binding; and (3) a tetrad of amino acids most important in catalysis: D50, Y55, K84 and H117 (based on the nomenclature of AKR1C9). In fact, although substrate specificity varies significantly among AKRs, including sugar aldehydes, ketosteroids, aflatoxin dialdehydes and polycyclic aromatic *trans*-dihydrodiols, most AKR enzymes catalyze the interconversion of aldehydes and ketones with primary and secondary alcohols. However, AKR1D enzymes are a notable exception. Instead of reducing an aldehyde or ketone group, they catalyze the reduction of double bonds in Δ^4 -3-ketosterols in a stereo-specific manner [3,4], and consequently, these enzymes are also known as steroid 5 β -reductases. Considering the difference between functionalities of these two enzymes, aldehyde/ketone reduction and double bond reduction, it is remarkable that a single amino acid substitution in the catalytic tetrad, from histidine to glutamate, is sufficient to achieve this switch from one function to another [5]. The recently determined crystal structure of AKR1D1 further elaborates the role of this residue where it is proposed to act as a superacid and in concert with the catalytic Tyrosine facilitates hydride transfer to the Δ^4 -ene [6]. Furthermore, strict conservation of this glutamate in all AKR1D proteins and almost complete absence from other subfamilies highlights the importance of this substitution for 5 β -reductase function.

2. The physiological role of AKR1D1 in bile acid biosynthesis

Steroid 5 β -reductase activity is most abundant in the liver and led to the first isolation of the protein from rat liver [7]. More than 25 years later, the human gene, AKR1D1, was cloned based on a previously released rat 5 β -reductase cDNA annotation [3,8]. Like its rat homolog, AKR1D1 is most abundant in liver and recombinant expression of the human protein in mammalian cells confirmed 5 β -reductase activity towards steroids and bile acid intermediates [3,9,10].

In congruence with the enzyme's expression pattern and catalytic activity, AKR1D1 has been proposed to play a physiological role in steroid hormone metabolism as well as bile acid biosynthesis. In the latter, AKR1D1 catalyzes the central 5 β -reduction step and reduces bile acid precursors such as Δ^4 -cholesten-7 α -ol-3-one and Δ^4 -cholestene-7 α ,12 α -diol-3-one to 5 β -cholestan-7 α -ol-3-one and 5 β -cholestane-7 α ,12 α -diol-3-one, respectively. The stereo-specific reduction of the sterol precursors is of physiological importance. While 5 α -reduction leaves the overall structure in its planar shape, 5 β -reduction introduces a 90° angle between the A and B ring. Sterols with this characteristic 5 β -reduced structure occur in the bile acids of almost all mammals and this configuration is essential for the proper emulsification of dietary cholesterol, lipids, and essential nutrients and promotion of their absorption and digestion [11,12].

Evidence that AKR1D1 is the only human 5 β -reductase and that its most important physiological role is in bile acid biosynthesis comes from patients with 5 β -reductase

deficiency, a metabolic syndrome first described by Setchell in 1988 [13]. The deficiency syndrome develops in infants within the first few weeks after birth and is characterized by reduced primary bile acid synthesis and accumulation of Δ^4 -3-keto- and 5 α -reduced (*allo*-) bile acids (Fig 1). Furthermore, 5 β -reduced steroids are absent from serum and urine. The effects of this rare metabolic disorder are severe and manifest in cholestasis and neo-natal liver damage probably caused by the accumulation of potentially cholestatic and hepatotoxic atypical bile acids. If untreated, 5 β -reductase deficiency is often lethal. Loss of 5 β -reductase activity could either result from a genetically determined enzyme defect or from secondary effects such as changes in protein/mRNA stability due to liver disease [14] or enzyme modification through chemical modification [15,16].

3. Disease associated AKR1D1 mutations affect conserved protein sites

In an effort to link putative genetic defects in AKR1D1 to the 5 β -reductase deficiency syndrome, the genotype of AKR1D1 had been determined in several patients. Sequencing identified missense mutations leading to truncated, non-functional proteins in two patients [17,18], and five individual point mutations leading to non-synonymous amino acid substitutions in the AKR1D1 protein (L106F, P133R, P198L, G223E, and R261C) in three other patients [17–19]. Analysis of the mutations in the AKR1D1 crystal structure however, did not reveal involvement of the affected residues in catalysis or cofactor or substrate binding [6]. Therefore, it remained unclear whether the detected mutations could indeed cause the 5 β -reductase deficiency phenotype observed in these patients.

Non-synonymous mutations not involved in enzyme function may still affect protein folding and stability if they are found within highly conserved residues or domains of a protein family. In this case, conservation reflects less the enzyme properties associated with catalysis but rather establishment of the common and characteristic protein fold of a family. These cues are the basis for instance in sequence based algorithms that identify conserved domains (e.g. CD search at NCBI) [20,21]) or in homology modeling (examples for AKR1D1 include [22,23]). To test this hypothesis we examined sequence conservation within the AKR1 family (Fig. 2). We find that all the AKR1D1 mutations occur either in conserved residues or conserved domains. Of these, two mutations, L106F and R261C, reside in α -helices 3 and 8, respectively, and could affect protein stability. The remaining mutations are located in loop or turn regions of the protein. These mutations severely alter the physico-chemical properties of the residue at the affected site. In two cases, the small but rigid proline is replaced by either a large positively charged amino acid (P133R) or a similar small hydrophobic, but flexible side chain (P198L). In G223E, the α -hydrogen is replaced by a carboxylic acid side chain. It is notable, that two mutations, P133R and G223E, reside in loops A and B, respectively, which convey substrate recognition and binding properties. These findings support the notion that the observed mutations could indeed result in changes in protein structure and stability and ultimately lead to deficient 5 β -reductase activity.

4. Disease associated AKR1D1 mutations affect protein integrity and enzyme activity

Further evidence of diminished structural integrity comes from our efforts to purify and enzymatically characterize the mutant AKR1D1 isoforms, and from monitoring expression levels and stability of these mutants when expressed in human cells. Recombinant protein expression in *E.coli* yielded abundant protein in lysed cells [24]. However, subsequent efforts to isolate the enzymes either failed or yielded extremely low amounts of purified protein in comparison to the wild type enzyme (Table 1). Only the P133R mutant was obtained in sufficient purity and amounts that allowed further characterization. Determination of melt curves by CD spectroscopy revealed decreased thermal stability of

the P133R mutant in the absence of cofactor. Melt curves were recorded following the absorbance at 222 nm while raising the temperature from 14 to 94 °C in increments of 2 °C. The T_m , the temperature where half of the protein was unfolded according to measurement of molar ellipticity, was 41°C for the mutant compared to 48°C for the wild type protein. However, presence of cofactor eliminated the observed difference [24]. Following expression of recombinant AKR1D1 in HEK 293 cells, levels of mutant proteins were significantly decreased compared to wild type (Fig 3). For two of the mutations, L106F and R261C, protein expression levels were less than 1% of that of the wild type enzyme. In addition, cycloheximide treatment revealed decreased stability of mutant protein as expression levels declined compared to wild type AKR1D1 over a 24 h time course.

However, the mutations observed in patients with 5 β -reductase deficiency not only affected expression levels and stability but also enzymatic activity. A study of the purified P133R mutant revealed drastic changes in kinetic constants with different steroid and bile acid intermediate substrates (Table 2). With Δ^4 -cholesten-7 α -ol-3-one as substrate the reaction proceeded with a highly reduced K_m and k_{cat} and kinetics were reminiscent of uncompetitive inhibition. Hence, the P133R mutation converts AKR1D1 from a low affinity, high capacity enzyme, to one with high affinity and low capacity. The mutant enzymes also showed severely decreased enzymatic activity when compared to wild type following expression in human HEK293 cells. The AKR1D1 mutants P198L and G223E did not show measurable 5 β -reductase activity after 60 h following addition of substrate to the culture medium. The mutants L106F, P133R and R261C exhibited 5 β -reductase activity that was only a fraction of that of wild type AKR1D1 (Fig 4). Quite notably, L106F and R261C showed detectable enzyme activity despite extremely low expression levels indicating that these mutations did not necessarily affect enzyme activity and that low protein expression accounted for their reduced activity in the HEK-293 cells.

5. Conclusions

In the AKR family, AKR1D1 is the only enzyme that does not catalyze the interconversion of aldehyde and ketone groups with primary and secondary alcohols but instead catalyzes the reduction of double bonds in Δ^4 -3-ketosteroids and sterols. In contrast to the closely related AKR1C subfamily, only one functional AKR1D1 gene is present in all vertebrates except fish. Furthermore, compared to other AKR1 family members the number of SNPs and other genomic variations is low in AKR1D1 [25] and sequence conservation between distantly related 5 β -reductase members is significantly higher than between 5 α -reductase homologs [26]. This agrees well with the central physiological function of AKR1D1 in bile acid biosynthesis, an important metabolic pathway in all vertebrates. Defects in bile acid metabolism are rare (<0.1% of population) but can have severe consequences, as seen in patients with 5 β -reductase deficiency. We showed that five mutations detected in these patients had either reduced protein expression and stability or enzyme activity, or both. As a result, net levels of physiologically active 5 β -reductase would be drastically reduced. Although the disease-associated mutations did not seem to directly affect substrate binding or catalysis, they significantly altered physico-chemical properties of conserved residues or areas within the protein thereby disrupting stability and enzymatic activity of AKR1D1.

Acknowledgments

We thank Dr. Robert Brown for his advice on using cycloheximide in measuring protein stability in cell culture. R.M. was supported by USPHS NIH grant R13-AA019612 to present this work at the 15th International Meeting on Enzymology and Molecular Biology of Carbonyl Metabolism in Lexington, KY USA. This work was supported by grants NIH 5-R01-DK047015-13 and P30-ES013508 awarded to T.M.P.

References

1. Drury, JE.; Hyndman, D.; Yin, J.; Penning, TM. The Aldo-Keto Reductase Superfamily Homepage: 2006 Update. In: Weiner, H.; Maser, E.; Lindahl, R.; Plapp, B., editors. *Enzymology and Molecular Biology of Carbonyl Metabolism*. West Lafayette, Indiana: Purdue University Press; 2007.
2. Jez JM, Flynn TG, Penning TM. A new nomenclature for the aldo-keto reductase superfamily. *Biochem Pharmacol*. 1997; 54(6):639–647. [PubMed: 9310340]
3. Kondo KH, Kai MH, Setoguchi Y, Eggertsen G, Sjoblom P, Setoguchi T, Okuda KI, Bjorkhem I. Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme. *Eur J Biochem*. 1994; 219(1–2):357–363. [PubMed: 7508385]
4. Okuda A, Okuda K. Purification and characterization of delta 4-3-ketosteroid 5 beta-reductase. *J Biol Chem*. 1984; 259(12):7519–7524. [PubMed: 6736016]
5. Jez JM, Penning TM. Engineering steroid 5 beta-reductase activity into rat liver 3 alpha-hydroxysteroid dehydrogenase. *Biochemistry*. 1998; 37(27):9695–9703. [PubMed: 9657682]
6. Di Costanzo L, Drury JE, Penning TM, Christianson DW. Crystal structure of human liver Delta4-3-ketosteroid 5beta-reductase (AKR1D1) and implications for substrate binding and catalysis. *J Biol Chem*. 2008; 283(24):16830–9. [PubMed: 18407998]
7. Berseus O. Conversion of cholesterol to bile acids in rat: purification and properties of a delta-4-3-ketosteroid 5-beta-reductase and a 3-alpha-hydroxysteroid dehydrogenase. *Eur J Biochem*. 1967; 2(4):493–502. [PubMed: 4384270]
8. Onishi Y, Noshiro M, Shimosato T, Okuda K. Molecular cloning and sequence analysis of cDNA encoding delta 4-3-ketosteroid 5 beta-reductase of rat liver. *FEBS Lett*. 1991; 283(2):215–218. [PubMed: 1710579]
9. Iyer RB, Binstock JM, Schwartz IS, Gordon GG, Weinstein BI, Southren AL. Human hepatic cortisol reductase activities: enzymatic properties and substrate specificities of cytosolic cortisol delta 4-5 beta-reductase and dihydrocortisol-3 alpha-oxidoreductase(s). *Steroids*. 1990; 55(11):495–500. [PubMed: 2075615]
10. Charbonneau A, The VL. Genomic organization of a human 5beta-reductase and its pseudogene and substrate selectivity of the expressed enzyme. *Biochim Biophys Acta*. 2001; 1517(2):228–235. [PubMed: 11342103]
11. Russell DW, Setchell KD. Bile acid biosynthesis. *Biochemistry*. 1992; 31(20):4737–4749. [PubMed: 1591235]
12. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. *Annu Rev Biochem*. 2003; 72:137–174. [PubMed: 12543708]
13. Setchell KD, Suchy FJ, Welsh MB, Zimmer-Nechemias L, Heubi J, Balistreri WF. Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis. *J Clin Invest*. 1988; 82(6):2148–2157. [PubMed: 3198770]
14. Clayton PT. Delta 4-3-oxosteroid 5 beta-reductase deficiency and neonatal hemochromatosis. *J Pediatr*. 1994; 125(5 Pt 1):845–846. [PubMed: 7965448]
15. Zhu Y, Fillenwarth MJ, Crabb D, Lumeng L, Lin RC. Identification of the 37-kd rat liver protein that forms an acetaldehyde adduct in vivo as delta 4-3-ketosteroid 5 beta-reductase. *Hepatology*. 1996; 23(1):115–122. [PubMed: 8550030]
16. Lin RC, Fillenwarth MJ, Du X. Cytotoxic effect of 7alpha-hydroxy-4-cholesten-3-one on HepG2 cells: hypothetical role of acetaldehyde-modified delta4-3-ketosteroid-5beta-reductase (the 37-kd-liver protein) in the pathogenesis of alcoholic liver injury in the rat. *Hepatology*. 1998; 27(1):100–107. [PubMed: 9425924]
17. Ueki I, Kimura A, Chen HL, Yorifuji T, Mori J, Itoh S, Maruyama K, Ishige T, Takei H, Nittono H, Kurosawa T, Kage M, Matsuishi T. SRD5B1 gene analysis needed for the accurate diagnosis of primary 3-oxo-Delta4-steroid 5beta-reductase deficiency. *J Gastroenterol Hepatol*. 2009; 24(5):776–785. [PubMed: 19175828]
18. Lemonde HA, Custard EJ, Bouquet J, Duran M, Overmars H, Scambler PJ, Clayton PT. Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. *Gut*. 2003; 52(10):1494–1499. [PubMed: 12970144]

19. Gonzales E, Cresteil D, Baussan C, Dabadie A, Gerhardt MF, Jacquemin E. SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-reductase deficiency: evidence for primary genetic defect. *J Hepatol.* 2004; 40(4):716–718. [PubMed: 15030995]
20. Marchler-Bauer A, Panchenko AR, Ariel N, Bryant SH. Comparison of sequence and structure alignments for protein domains. *Proteins.* 2002; 48(3):439–446. [PubMed: 12112669]
21. Marchler-Bauer A, Bryant SH. CD-Search: protein domain annotations on the fly. *Nucleic Acids Res.* 2004; 32(Web Server issue):W327–331. [PubMed: 15215404]
22. Jez JM, Bennett MJ, Schlegel BP, Lewis M, Penning TM. Comparative anatomy of the aldo-keto reductase superfamily. *Biochem J.* 1997; 326(Pt 3):625–636. [PubMed: 9307009]
23. Lee WH, Lukacik P, Guo K, Ugochukwu E, Kavanagh KL, Marsden B, Oppermann U. Structure-activity relationships of human AKR-type oxidoreductases involved in bile acid synthesis: AKR1D1 and AKR1C4. *Mol Cell Endocrinol.* 2009; 301(1–2):199–204. [PubMed: 19013211]
24. Drury JE, Mindnich R, Penning TM. Characterization of disease-related 5beta-reductase (AKR1D1) mutations reveals their potential to cause bile acid deficiency. *J Biol Chem.* 2010; 285(32):24529–37. [PubMed: 20522910]
25. Mindnich RD, Penning TM. Aldo-keto reductase (AKR) superfamily: genomics and annotation. *Hum Genomics.* 2009; 3(4):362–370. [PubMed: 19706366]
26. Langlois VS, Zhang D, Cooke GM, Trudeau VL. Evolution of steroid-5alpha-reductases and comparison of their function with 5beta-reductase. *Gen Comp Endocrinol.* 166(3):489–497. [PubMed: 19686747]

Figure 1. Central role of 5β-reduction in bile acid biosynthesis

AKR1D1 is a key enzyme in bile acid biosynthesis that catalyzes the 5β-reduction of Δ^4 -cholesten-7 α -ol-3-one and Δ^4 -cholestene-7 α ,12 α -diol-3-one substrates that will ultimately result in the production of mature bile acids such as chenodeoxycholic and cholic acid. If 5β-reduction is inhibited through a functional defect in AKR1D1 or other factors, 5β-reductase deficiency syndrome is observed. Physiological consequences include cholestasis and liver damage and often result in death of the patient if untreated.

Figure 2. Disease-associated mutations affect regions highly conserved in the AKR1 family
Multiple sequence alignment and calculation of conservation per site of AKR1 sequences annotated at the AKR website was performed with ClustalW and relative conservation visualized with JalView. Amino acid position in AKR1D1 is indicated on the x-axis; degree of conservation on the y-axis. Residues mutated in patients with 5 β -reductase deficiency syndrome are indicated in black; the residues forming the catalytic tetrad are marked in light grey. Secondary structure elements of AKR1D1 are indicated above the plot. Notably, residues changed in the disease are highly conserved or are located in a highly conserved region of the protein.

Figure 3. AKR1D1 disease mutants showed reduced protein expression and stability versus wild type enzyme

Expression of wild type and mutant AKR1D1 in HEK 293 cells was observed by Western Blotting with a specific anti-AKR1D1 antibody. Expression levels were determined with densitometry and analysis with the Uniscan and imageJ software packages. Expression levels of the L106F and R261C mutants were so low that they could only be detected by a highly sensitive detection method (SuperSignal West Femto Kit (Thermo Scientific)).

Figure 4. AKR1D1 disease mutants had reduced or no enzyme activity when expressed in HEK-293 cells

Wild type and mutant AKR1D1 were expressed in HEK 293 cells and 5 β -reductase activity was measured radiometrically by following the conversion of tritiated testosterone to 5 β -DHT. Product verification and quantification was carried out by thin layer chromatography. Initial velocities were estimated from linear phase of product formation. In case of the mutants P198L and G223E no substrate conversion was detected within 60 h following addition of testosterone to the medium.

Table 1

Purification of recombinant AKR1D1 mutant protein

Ni-sepharose fraction of	Volume (mL)	Total protein (mg)	Total activity (nmol min ⁻¹)	Specific activity (nmol min ⁻¹ mg ⁻¹)	Purification factor	Yield (%)
WT	4.0	5.7	462	81	9.9	56
L106F*	14.5	3.3	0.2	0.05	1.25	7
P198L	3.9	0.4	ND	ND	-	0
R261C	4.1	0.5	ND	ND	-	0
P133R	5.0	1.5	36	24.4	9.47	16

* By SDS-PAGE analysis, sample is only 10% pure.

Table 2Effect of the P133R mutation on K_m and k_{cat} of 5 β -reduction

	wild type		P133R mutant	
	k_{cat} (min ⁻¹)	K_m (μ M)	k_{cat} (min ⁻¹)	K_m (μ M)
testosterone	7.1 $\pm$ 1.7	2.7 $\pm$ 1.2	2.7 $\pm$ 0.3	12.7 $\pm$ 2.2
cortisone	9.9 $\pm$ 0.1	15.1 $\pm$ 0.3	0.6 $\pm$ 0.02	1.3 $\pm$ 0.1
4-cholestene-7 α -ol-3-one	1.7 $\pm$ 0.1	0.8 $\pm$ 0.2	0.2 *	0.08 *

Activity measurements were determined fluorimetrically.

*
estimated